Chimeric Therapeutics Limited ASX: CHM Share Price & Review

CHM Overview

CHM Health Scores

Short Term

Mean Reversion

Neutral

Trend

Neutral

Event

Neutral

Halo Model

MQV

Very Weak

GARP

Very Weak

MQV Small

Neutral

Valuation

Value

Consensus

Momentum

Price

Very Weak

Earnings

Very Weak

Growth

Earnings

Very Weak

Dividends

Very Weak

Quality

Capital Efficiency

Very Weak

Balance Sheet

Very Weak

About CHM

Website

N/A

Telephone

61.3.9824.5254

Address

Level 3 62 Lygon Street Carlton, Victoria (VIC) 3053

Description

Chimeric Therapeutics Ltd. is a clinical stage cell therapy company, which engages in the development and commercialization of cell therapies in oncology. Its products include NK Cell Derived Allogenic Therapies and T Cell Derived Autologous Therapies. The company was founded by Paul A. Hopper in 2020 and is headquartered in Carlton South, Australia.

CHM Price Chart

Key Stats

Market Cap

AU$9.76M

N/A

EV/EBITDA

N/A

Dividends Overview

DIV Yield

N/A

Franking

N/A

Ex Dividend Date (est.)

N/A

Market Data

52 weeks range

Low 0.0 - 0.02

Trade Value (12mth)

AU$7,417.00

1 week

1 month

-25%

YTD

-55%

1 year

-79%

All time high

0.40

Key Fundamentals

EPS 3 yr Growth

-81.70%

EBITDA Margin

-446.70%

Operating Cashflow

-$7m

Free Cash Flow Return

-327.40%

ROIC

-469.40%

Interest Coverage

N/A

Quick Ratio

0.70

Other Data

Shares on Issue (Fully Dilluted)

2015m

HALO Sector

Healthcare

Next Company Report Date

27-Aug-26

Ex Dividend Date (est.)

N/A

Next Dividend Pay Date (est.)

N/A

Reporting Currency

AUD

Short Sell (% of issue)

0.01

CHM Announcements

Latest Announcements

Date	Announcements
09 September 25	Presentation to investor webinar × Presentation to investor webinar
29 August 25	Appendix 4E and Annual Report × Appendix 4E and Annual Report
29 August 25	Corporate Governance Statement and Appendix 4G × Corporate Governance Statement and Appendix 4G
26 August 25	Webinar - CHM CDH17 deep dive with Professor Jennifer Eads × Webinar - CHM CDH17 deep dive with Professor Jennifer Eads
21 August 25	Change of Director's Interest Notice MP × Change of Director's Interest Notice MP
07 August 25	Application for quotation of securities - CHM × Application for quotation of securities - CHM
07 August 25	Notification regarding unquoted securities - CHM × Notification regarding unquoted securities - CHM
04 August 25	CHM CDH17 Clinical Trial Update × CHM CDH17 Clinical Trial Update
29 July 25	Quarterly Activities/Appendix 4C Cash Flow Report × Quarterly Activities/Appendix 4C Cash Flow Report
29 July 25	Change in substantial holding - PH × Change in substantial holding - PH
28 July 25	Proposed issue of securities - CHM × Proposed issue of securities - CHM
25 July 25	Application for quotation of securities - CHM × Application for quotation of securities - CHM
25 July 25	Notification regarding unquoted securities - CHM × Notification regarding unquoted securities - CHM
25 July 25	Application for quotation of securities - CHM × Application for quotation of securities - CHM
25 July 25	Notification regarding unquoted securities - CHM × Notification regarding unquoted securities - CHM
24 July 25	Update - Proposed issue of securities - CHM × Update - Proposed issue of securities - CHM
23 July 25	Presentation to Extraordinary General Meeting × Presentation to Extraordinary General Meeting
23 July 25	Results of Meeting × Results of Meeting
23 July 25	Prospectus × Prospectus
23 July 25	Proposed issue of securities - CHM × Proposed issue of securities - CHM
02 July 25	Initial Director's Interest Notice × Initial Director's Interest Notice
01 July 25	Professor Miles Prince appointed as Non-Executive Director × Professor Miles Prince appointed as Non-Executive Director
01 July 25	Change of Director's Interest Notice LR × Change of Director's Interest Notice LR
26 June 25	Notification of cessation of securities - CHM × Notification of cessation of securities - CHM
24 June 25	Notice of Extraordinary General Meeting/Proxy Form × Notice of Extraordinary General Meeting/Proxy Form
17 June 25	Translational data shows persistence of CHM CDH17 × Translational data shows persistence of CHM CDH17

Dividends

Key Stats

Ex Dividend Date (est.)

N/A

DIV Yield

N/A

Franking Level

N/A

DPSg

N/A

Quality Yield

Falling Divs over next 2

Values and Recommendations

Key Stats

Consensus Score

Recommendation

EPS 1 month Change

Quality Yield

Falling Divs over next 2

Halo Consensus Score

PEG Ratio

Consensus EPS Revisions

Short selling

Key Stats

Percent of Issue

0.00%

Value ($M)

0

Prior Change

N/A

7 Day Change

N/A

1 Month Change

N/A

3 Month Change

N/A

Discover
Short-selling
Opportunities

Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.

CHM Shortsell

Frequently Asked Questions

What is the current share price of Chimeric Therapeutics Limited (CHM:ASX)?

The current share price of Chimeric Therapeutics Limited (CHM:ASX) is AU$0.004.

What is the 52-week high share price for Chimeric Therapeutics Limited (CHM:ASX)?

The 52-week high share price for Chimeric Therapeutics Limited (CHM:ASX) is AU$0.02.

What is the 52-week low share price for Chimeric Therapeutics Limited (CHM:ASX)?

The 52-week low share price for Chimeric Therapeutics Limited (CHM:ASX)? is AU$0.00.

What is the dividend yield for Chimeric Therapeutics Limited (CHM:ASX)?

Chimeric Therapeutics Limited (CHM:ASX) does not pay a dividend.

What was Chimeric Therapeutics Limited (CHM:ASX) last dividend payment?

Chimeric Therapeutics Limited (CHM:ASX) does not pay a dividend.

What is the franking level for Chimeric Therapeutics Limited (CHM:ASX)?

Chimeric Therapeutics Limited (CHM:ASX) has a franking level of 0.0%.

In which sector is Chimeric Therapeutics Limited (CHM:ASX) classified?

Chimeric Therapeutics Limited (CHM:ASX) is classified in the Healthcare.

The current P/E ratio for Chimeric Therapeutics Limited (CHM:ASX) is .